A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: Primary results of the ARISE trial

被引：0
|
作者：
Ashina, M. [1 ,2 ]
Dodick, D. [3 ]
Kudrow, D. [4 ]
Lanteri-Minet, M. [5 ,6 ]
Osipova, V.
Palmer, K. [7 ]
Picard, H. [8 ]
Mikol, D. [8 ]
Lenz, R. [8 ]
机构：
[1] Univ Copenhagen, Danish Headache Ctr, Rigshosp Glostrup, Fac Med & Hlth Sci, Copenhagen, Denmark
[2] Univ Copenhagen, Dept Neurol, Rigshosp Glostrup, Fac Med & Hlth Sci, Copenhagen, Denmark
[3] Mayo Clin, Scottsdale, AZ USA
[4] Calif Med Clin Headache, Santa Monica, CA USA
[5] CHU, Pain Dept, Nice, France
[6] CHU, FHU InovPain, Nice, France
[7] Amgen Inc, Cambridge, England
[8] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2017年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PR1045
引用
收藏
页码：470 / 470
页数：1
相关论文
共 50 条
  • [41] EFFICACY AND SAFETY OF ELAFIBRANOR IN PRIMARY BILIARY CHOLANGITIS: RESULTS FROM THE ELATIVE T DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL
    Bowlus, Christopher L.
    Kowdley, Kris V.
    Levy, Cynthia
    Akarca, Ulus
    Alvares-Da-Silva, Mario Reis
    Andreone, Pietro
    Arrese, Marco
    Corpechot, Christophe
    Francque, Sven
    Heneghan, Michael A.
    Invernizzi, Pietro
    Jones, David
    Kruger, Frederik C.
    Lawitz, Eric
    Mayo, Marlyn J.
    Shiffman, Mitchell L.
    Swain, Mark G.
    Valera, Jose Miguel
    Vargas, Victor
    Vierling, John M.
    Villamil, Alejandra
    Addy, Carol
    Dietrich, Julie
    Germain, Jean-Michel
    Mazain, Sarah
    Rafailovic, Dragutin
    Tadde, Bachirou
    Miller, Benjamin
    Shu, Jianfen
    Zein, Claudia O.
    Schattenberg, Joern M.
    HEPATOLOGY, 2024, 79 (02) : E40 - E42
  • [42] Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies
    Hirata, Koichi
    Takeshima, Takao
    Sakai, Fumihiko
    Imai, Noboru
    Matsumori, Yasuhiko
    Tatsuoka, Yoshihisa
    Numachi, Yotaro
    Yoshida, Ryuji
    Peng, Cheng
    Mikol, Daniel D.
    Lima, Gabriel Paiva da Silva
    Cheng, Sunfa
    BRAIN AND BEHAVIOR, 2022, 12 (03):
  • [43] Reducing the impact of migraine on functioning: Results from the STRIVE trial, a phase 3, randomised, double-blind, placebo-controlled study of erenumab in patients with episodic migraine
    Buse, Dawn C.
    Lipton, Richard B.
    Mikol, Daniel D.
    Thach, Andrew V.
    Desai, Pooja
    Picard, Hernan
    Kubo, Yumi
    Hareendran, Asha
    Kawata, Ariane K.
    JOURNAL OF HEADACHE AND PAIN, 2017, 18
  • [44] A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
    Schmidt, Wolfgang A.
    Dasgupta, Bhaskar
    Sloane, Jennifer
    Giannelou, Angeliki
    Xu, Yuqing
    Unizony, Sebastian H.
    Mackie, Sarah L.
    Gonzalez-Gay, Miguel A.
    Spiera, Robert
    Warrington, Kenneth J.
    Villiger, Peter M.
    Nivens, Michael C.
    Akinlade, Bolanle
    Lin, Yong
    Buttgereit, Frank
    Stone, John H.
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
  • [45] A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
    Wolfgang A. Schmidt
    Bhaskar Dasgupta
    Jennifer Sloane
    Angeliki Giannelou
    Yuqing Xu
    Sebastian H. Unizony
    Sarah L. Mackie
    Miguel A. Gonzalez-Gay
    Robert Spiera
    Kenneth J. Warrington
    Peter M. Villiger
    Michael C. Nivens
    Bolanle Akinlade
    Yong Lin
    Frank Buttgereit
    John H. Stone
    Arthritis Research & Therapy, 25
  • [46] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
    Mullin, K.
    Croop, R.
    Pavlovic, J.
    Mosher, L.
    Smith, T.
    Madonia, J.
    Lovegren, M.
    Coric, V.
    Lipton, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [47] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
    Mullin, Kathleen
    Croop, Robert
    Pavlovic, Jelena
    Mosher, Linda
    Smith, Timothy
    Madonia, Jennifer
    Lovegren, Meghan
    Lipton, Richard
    NEUROLOGY, 2023, 100 (17)
  • [48] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
    Mullin, Kathleen
    Croop, Robert
    Pavlovic, Jelena M.
    Mosher, Linda
    Smith, Timothy R.
    Madonia, Jennifer
    Lovegren, Meghan
    Coric, Vladimir
    Lipton, Richard B.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 126 - 127
  • [49] Efficacy and safety of zavegepant nasal spray for the acute treatment of migraine: Results of a phase 3 double-blind, randomized, placebo controlled trial
    Mullin, K.
    Croop, R.
    Pavlovic, J. M.
    Mosher, L.
    Smith, T. R.
    Madonia, J.
    Lovegren, M.
    Coric, V
    Lipton, R. B.
    HEADACHE, 2022, 62 : 128 - 129
  • [50] Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab
    Zhang, Yanyan
    Pei, Zhaohui
    Chen, Beijian
    Qu, Yanling
    Dong, Xiaolin
    Yu, Binge
    Wang, Guoqin
    Xu, Fang
    Lu, Dongmei
    He, Zhimei
    Chen, Benchao
    Ma, Lei
    Wang, Max
    Li, Baiyong
    Xia, Michelle
    Zheng, Bo
    Huo, Yong
    PHARMACOLOGICAL RESEARCH, 2024, 207
12345